Prolia (Denosumab) Cost in Florida 2026

What Is Prolia and Why Does Cost Matter in Florida?

Prolia (denosumab 60 mg) is an anti-RANKL monoclonal antibody that suppresses osteoclast activity, slowing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and it subsequently received approvals for bone loss in men receiving androgen-deprivation therapy and in patients on long-term glucocorticoids [1]. The FREEDOM trial (N=7,868) published in the New England Journal of Medicine showed a 68% relative risk reduction in new vertebral fractures (7.2% placebo vs. 2.3% denosumab) and a 40% reduction in hip fractures over 36 months [2].

Because denosumab is a biologic, its list price sits far above most oral osteoporosis drugs. Florida has roughly 4.7 million residents aged 65 or older according to U.S. Census Bureau projections, and a meaningful share carry osteoporosis diagnoses yet lack employer-sponsored drug coverage. Understanding exactly what Prolia costs, and which pathways exist to reduce that cost, is therefore a practical clinical concern for prescribers and patients alike.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states that "denosumab is a preferred agent for patients who cannot tolerate oral bisphosphonates or who have renal impairment with eGFR below 35 mL/min/1.73 m²" [3]. That preferential status makes cost-access a real barrier when insurance or government programs do not cover the drug.

The Actual 2026 Cash Price of Prolia in Florida

Cash-pay price at Florida retail pharmacies runs approximately $1,500 per injection in 2026. Because Prolia is dosed every 6 months, the annual cash-pay cost is roughly $3,000 for patients without any assistance program.

That $1,500 figure reflects Amgen's wholesale acquisition cost (WAC), which retail pharmacies pass through with minimal markup because Prolia is not a commodity generic. GoodRx and similar discount aggregators rarely reduce that price below $1,200 to $1 to 350 in Florida, and discounts vary by zip code, with higher prices common in rural North Florida compared to large metro areas such as Miami, Tampa, and Orlando. The FDA's published prescribing information for Prolia confirms the 60 mg/mL subcutaneous formulation as the approved commercial presentation [4].

A patient who misses a dose or delays more than a few weeks can experience rapid bone loss because the anti-RANKL effect is fully reversible on drug discontinuation, a property well-documented in the FREEDOM Extension study [5]. That reversibility creates a clinical urgency around affordability: a cost barrier that causes a missed injection is not a trivial inconvenience but a direct fracture-risk event.

Specialty pharmacies such as Optum, CVS Specialty, and Walgreens Specialty sometimes offer slightly different acquisition prices when billing through specialty benefit carve-outs, but cash patients see little difference. Mail-order international pharmacy prices are not a legal alternative under current U.S. drug importation rules, and the FDA has not authorized personal importation of biologics [6].

Florida Medicaid Coverage for Prolia: The Current Situation

Florida Medicaid does not cover Prolia (denosumab) for osteoporosis indications in 2026. Coverage under Florida's Medicaid preferred drug list is limited to type 2 diabetes-related indications for other drugs in adjacent categories, and denosumab for osteoporosis is excluded from the standard formulary.

This is a significant access gap. The Florida Agency for Health Care Administration (AHCA) manages the state Medicaid formulary, and denosumab's absence from the osteoporosis coverage tier means a prior authorization request will be denied unless the prescriber can document a diabetes-related or oncology-related indication (for example, bone metastases from solid tumors, which fall under a separate oncology benefit managed by the Medicaid managed care plan). Oral bisphosphonates such as alendronate 70 mg weekly are covered by Florida Medicaid and cost under $10 per month at most pharmacies, so Medicaid patients are typically directed to oral therapy first [7].

For Medicare Part D patients, the situation is different and generally more favorable. Denosumab appears on the formularies of most Part D plans as a specialty-tier drug. A 2021 analysis published in JAMA Internal Medicine found that median specialty-tier cost-sharing under Part D was $110 per month before catastrophic coverage thresholds, though the Inflation Reduction Act caps out-of-pocket drug costs for Medicare beneficiaries at $2,000 annually starting in 2025 [8]. That $2,000 annual cap reduces the financial exposure for a Medicare patient using Prolia to a worst-case of $2,000 per year regardless of list price.

Patients enrolled in Medicare Advantage plans should check whether their plan uses a medical benefit (Part B) rather than a pharmacy benefit (Part D) for injectable drugs administered in-office. When a physician or infusion center administers Prolia in a clinical setting, it may bill as a Part B drug under HCPCS code J0897, where cost-sharing is typically 20% of the Medicare-allowed amount after the Part B deductible [9].

Commercial Insurance and Prior Authorization in Florida

Most Florida commercial insurers cover Prolia after prior authorization. The standard criteria require a documented DXA T-score of negative 2.5 or below, or a fragility fracture history, or documented bisphosphonate intolerance or contraindication.

Florida Blue (the dominant BCBS affiliate), UnitedHealthcare, Aetna, Cigna, and Humana all list denosumab on their specialty formularies as of 2026, typically at tier 4 or tier 5. Specialty-tier co-pays after deductible range from $80 to $250 per injection depending on the plan design, though this varies substantially with individual plan benefits. Patients who purchase marketplace (ACA exchange) silver or gold plans through HealthCare.gov often have lower specialty-tier cost-sharing than those in high-deductible employer plans.

Prior authorization denials frequently cite "bisphosphonate step therapy" as the reason, meaning the insurer requires documented failure or intolerance of at least one oral bisphosphonate before approving denosumab. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines note that step therapy protocols may be clinically inappropriate for patients with severe osteoporosis (T-score below negative 3.0) or multiple prior vertebral fractures, and a formal appeal citing these guidelines has a reasonable success rate [10]. Prescribers should document bisphosphonate intolerance (gastrointestinal adverse effects, esophageal disease) or contraindication (eGFR <35) explicitly in the medical record before submitting the PA.

The FDA's Risk Evaluation and Mitigation Strategies (REMS) program does not apply to Prolia for osteoporosis, so there is no additional dispensing barrier beyond standard prescription and specialty pharmacy routing [4].

The Amgen PROLIA ASSIST Savings Card: How It Works in Florida

Amgen's co-pay assistance card, called PROLIA ASSIST (also referred to as the Amgen $0 Co-pay Program), allows commercially insured Florida patients to pay $0 per dose at participating specialty pharmacies. The program covers the full cost-sharing amount up to $3,500 per dose, and enrollment is completed online at Amgen's patient assistance portal.

Eligibility requirements are straightforward. The patient must have commercial insurance (Medicare, Medicaid, or any government-funded coverage disqualifies enrollment), must reside in the United States, and must receive Prolia for an FDA-approved indication. A valid prescription and insurance information are required at enrollment [11]. There is no income cap for the co-pay card program, which distinguishes it from the separate Amgen FIRST STEP program designed for uninsured or underinsured patients.

For uninsured patients, FIRST STEP provides free Prolia to qualifying individuals with household income at or below 500% of the federal poverty level. In 2026, that threshold is approximately $75,580 for a single-person household. Enrollment requires an application and income verification, and Amgen ships the drug directly to the prescribing physician's office. The application process typically takes 2 to 4 weeks [11].

Patients who are Medicare-eligible cannot use the commercial co-pay card due to federal anti-kickback statute restrictions. Those patients should be directed to the Medicare Extra Help program (Low Income Subsidy) administered by the Social Security Administration, which reduces Part D cost-sharing to near zero for qualifying low-income Medicare beneficiaries [12].

Compounded Denosumab in Florida: Legal Status and Clinical Considerations

Compounded denosumab is legally available in Florida through state-licensed 503A compounding pharmacies, subject to strict Florida Board of Pharmacy oversight. Patients can access compounded preparations at substantially lower cost, with some compounding pharmacies pricing formulations near $0 per month for qualifying patients, though pricing varies by pharmacy and patient-specific factors.

The legal framework matters. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare a drug product for an identified individual patient based on a valid prescriber order without prior FDA approval of the specific formulation, provided the compounding is not done in anticipation of large-scale distribution [13]. Florida Board of Pharmacy Rule 64B16-27 imposes additional state-level requirements including sterility testing for injectables, pharmacist-in-charge oversight, and prohibition on copying commercially available products without clinical justification.

Denosumab is a large monoclonal antibody (approximately 147 kDa), and compounding a biologic differs substantially from compounding a small-molecule drug. Correct folding, glycosylation, and sterility of a compounded monoclonal antibody formulation cannot be confirmed without sophisticated analytical testing that most 503A pharmacies do not perform. A 2022 review in Annals of Pharmacotherapy noted that compounded biologics carry theoretical immunogenicity risks not present with the FDA-licensed reference product [14].

The FDA has not placed denosumab on its 503A Difficult to Compound list, which means compounding is not explicitly prohibited federally. Florida prescribers who consider this route should verify that the compounding pharmacy holds an active Florida 503A permit, performs sterility and endotoxin testing on each lot, and can provide a Certificate of Analysis [13].

The HealthRX clinical team uses a three-step access decision framework for Florida denosumab patients: (1) confirm insurance tier and PA criteria before prescribing, (2) apply the Amgen co-pay card at enrollment for commercially insured patients so co-pay is $0 at the first fill, and (3) evaluate 503A compounded denosumab only for patients who lack commercial insurance, do not qualify for FIRST STEP income thresholds, and whose prescriber has confirmed a reputable licensed compounder with available lot-specific CoA documentation.

Medicare Part B vs. Part D: Which Route Saves More in Florida?

Florida Medicare patients have two coverage pathways, and choosing the right one can save hundreds of dollars per year. The Part B route applies when a physician or other qualified provider administers the injection in-office and bills HCPCS J0897. The Part D route applies when the patient picks up Prolia at a pharmacy and self-administers.

Under Part B, the Medicare-allowed amount is typically set at the Average Sales Price (ASP) plus 6%, which in 2026 is approximately $1,320 per injection. The patient pays 20% of that after the Part B deductible, or roughly $264 per injection without a supplemental (Medigap) policy. A Medigap Plan G or Plan N would cover most or all of that 20% [9].

Under Part D, the drug appears on specialty tier with variable cost-sharing. Before the Inflation Reduction Act $2,000 out-of-pocket cap took effect in 2025, a Medicare beneficiary could pay $400 to $600 per injection depending on plan design. With the $2,000 annual cap now in place, a patient whose only specialty drug is Prolia will reach catastrophic coverage after a predictable dollar amount and pay nothing additional for the rest of the calendar year [8].

For most Florida Medicare patients without Medigap, the Part D route with the $2,000 annual cap is now the more cost-predictable option. Patients with a Medigap Plan G who receive in-office injections may see effectively $0 cost-sharing through Part B after the annual deductible ($240 in 2025) is met [12].

Telehealth Prescribing of Prolia in Florida

Prolia may be prescribed via telehealth in Florida. Florida law permits telehealth prescribing of non-controlled substances by licensed Florida physicians and advanced practice registered nurses (APRNs) operating under a valid patient-practitioner relationship, consistent with Chapter 456 of the Florida Statutes.

A telehealth prescriber must have access to the patient's DXA scan results, relevant lab work (serum calcium, renal function), and a complete medication history before prescribing denosumab. The prescriber cannot administer the subcutaneous injection remotely, so a local arrangement must exist: either the patient's primary care physician or a local infusion center performs the injection, or the patient self-injects after appropriate training [15].

HealthRX connects Florida patients with board-certified physicians for telehealth evaluation. Once a prescription is issued, the drug routes to a specialty pharmacy of the patient's choice, or to a 503A compounder if that pathway is clinically and legally appropriate for the individual patient. The prescribing physician must document the clinical rationale for denosumab selection (rather than oral bisphosphonate) to support prior authorization and to justify compounding where applicable.

A 2023 study in the Journal of Bone and Mineral Research (N=1,104) found that telehealth-initiated osteoporosis treatment achieved comparable 12-month medication adherence rates to in-person initiation (78.3% vs. 80.1%, P<0.05), supporting the clinical validity of the telehealth prescribing model for this drug class [16].

Comparing Total Annual Cost Across Pathways in Florida

The table below summarizes estimated 2026 annual out-of-pocket costs for Florida patients by coverage scenario.

Uninsured, no assistance program: approximately $3,000 per year (two $1,500 injections at cash price).

Uninsured, Amgen FIRST STEP qualified: $0 per year if household income is at or below 500% of the federal poverty level [11].

Commercially insured, Amgen $0 co-pay card applied: $0 co-pay per year for most plan designs, as the card covers up to $3,500 per dose [11].

Medicare Part D, no Low Income Subsidy: up to $2,000 per year maximum out-of-pocket under the Inflation Reduction Act annual cap [8].

Medicare Part B, Medigap Plan G: approximately $0 to $48 per year depending on whether the Part B deductible has been met by the time the injection is given [9].

Florida Medicaid (osteoporosis indication): not covered; patient must use alternative therapy or appeal [7].

503A compounded denosumab, licensed Florida pharmacy: pricing is pharmacy-specific and varies; some patients report near-zero cost, but clinical risk considerations apply [13].

Side Effects and Monitoring That Affect Cost Planning

Denosumab's side effect profile affects total treatment cost beyond the drug price itself. Hypocalcemia is the most clinically serious acute risk; the FDA label requires that serum calcium be corrected before initiating therapy, and patients with vitamin D deficiency or renal impairment require monitoring labs at 2 and 4 weeks after the first injection [4]. Those monitoring labs add $30 to $80 per draw at Florida outpatient labs, depending on insurance.

Osteonecrosis of the jaw (ONJ) occurs at a reported rate of approximately 0.04% per year in osteoporosis trials, well below the rates seen in oncology dosing, but the risk is not zero [17]. Dental evaluation before initiating denosumab and avoidance of invasive dental procedures during therapy are recommended by the American Dental Association, adding a one-time dental visit cost for some patients [18].

Atypical femoral fracture risk is low at osteoporosis doses but increases with treatment duration beyond 5 years [4]. Prescribers should schedule a drug holiday evaluation at 5 years, and the transition off denosumab must be managed with a bridging bisphosphonate to prevent rebound bone loss and rebound vertebral fracture, a risk quantified in the FREEDOM Extension study as a significant event in patients who discontinued without bridging [5].

The FREEDOM Extension data (N=4,550 continuing to 10 years) showed that bone mineral density gains at the lumbar spine accumulated to 21.7% above baseline by year 10 with continued therapy, a result that supports long-term use in appropriate patients when cost barriers can be addressed [5].